NextCure, Inc. (NASDAQ:NXTC) Receives $17.00 Consensus PT from Brokerages

Shares of NextCure, Inc. (NASDAQ:NXTCGet Rating) have been given an average recommendation of “Buy” by the six analysts that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $17.00.

Several research analysts recently issued reports on NXTC shares. Zacks Investment Research lowered shares of NextCure from a “buy” rating to a “hold” rating in a research report on Wednesday, March 9th. LADENBURG THALM/SH SH began coverage on shares of NextCure in a research note on Tuesday, March 1st. They issued a “buy” rating and a $16.00 price target for the company.

NASDAQ:NXTC traded down $0.11 during midday trading on Monday, hitting $4.16. The company had a trading volume of 92,302 shares, compared to its average volume of 113,563. NextCure has a 52-week low of $4.14 and a 52-week high of $9.29. The stock’s fifty day moving average price is $4.92 and its 200-day moving average price is $5.78. The company has a market capitalization of $115.32 million, a PE ratio of -1.66 and a beta of 0.01.

NextCure (NASDAQ:NXTCGet Rating) last announced its earnings results on Thursday, March 3rd. The company reported ($0.61) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.67) by $0.06. On average, sell-side analysts predict that NextCure will post -2.54 earnings per share for the current year.

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. raised its stake in shares of NextCure by 257.4% in the fourth quarter. JPMorgan Chase & Co. now owns 8,774 shares of the company’s stock worth $53,000 after purchasing an additional 6,319 shares during the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in NextCure during the fourth quarter valued at $60,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in NextCure during the third quarter valued at $99,000. Marquette Asset Management LLC increased its position in NextCure by 36.2% during the fourth quarter. Marquette Asset Management LLC now owns 17,500 shares of the company’s stock valued at $105,000 after acquiring an additional 4,652 shares during the last quarter. Finally, Cubist Systematic Strategies LLC increased its position in NextCure by 27.8% during the fourth quarter. Cubist Systematic Strategies LLC now owns 18,383 shares of the company’s stock valued at $110,000 after acquiring an additional 4,001 shares during the last quarter. 52.38% of the stock is owned by institutional investors.

About NextCure (Get Rating)

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors.

Further Reading

Analyst Recommendations for NextCure (NASDAQ:NXTC)

Receive News & Ratings for NextCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NextCure and related companies with MarketBeat.com's FREE daily email newsletter.